Can a virtual team of researchers break a 40-year logjam in this rare cancer?
John Carroll

August 25, 2025

When Mac Tichenor’s son Willie died of osteosarcoma at the age of 19 back in 2006, oncologists still relied on a decades-old chemo regimen called MAP β€” high-dose methotrexate, combined with doxorubicin and cisplatin. Typically, for young patients with the rare bone cancer, it staved off death for a while.

Read More at Endpoints News

UPDATES ANDΒ NEWS

Media Coverage

Why some family offices are becoming cancer research’s new bankrollers | Crain Currency

Media Coverage

𝖑𝗋𝖾𝖺𝗄 π˜›π˜©π˜³π˜°π˜Άπ˜¨π˜© 𝖒𝖺𝗇𝖼𝖾𝗋’π—Œ Tyler Jacks: β€œWe’ve created a new operating model for collaborative cancer research.

Insights & Updates

2025 Year in Review: Our Scientific Progress and Clinical Impact

BE PART OF THE MISSION
Stay Informed, Make an Impact

Subscribe

Be the first to hear about cutting-edge research, pioneering projects, and the latest advancements in Break Through Cancer science. Sign up to stay informed.

* indicates required
Email Format

Give

Your contribution fuels groundbreaking research in some of the most challenging cancers. Every gift accelerates progress. For more information please contact Michaela Forand at MF@breakthroughcancer.org or 1-800-757-9881 ext 2.

Media Coverage